Janssen Sciences Ireland UC

Clinical trials sponsored by Janssen Sciences Ireland UC, explained in plain language.

Now part of Johnson & Johnson JNJ NYSE

Pharmaceutical research and development subsidiary of Johnson & Johnson.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Not yet recruiting 1 Not yet finished but already full! 1 Completed 1

HIV patients get continued access to key drug in safety study

Disease control Completed

This study gave HIV-1 patients continued access to the drug etravirine until they could switch to a local treatment. It included 180 people aged 2 and older who had already benefited from the drug in a previous trial. The main goal was to monitor safety while providing the medica…

Phase 3 • Sponsor: Janssen Sciences Ireland UC • Aim: Disease control

Last updated Jun 27, 2026 13:04 UTC

Janssen Sciences Ireland UC

HIV patients get continued access to key drug in safety study